Caffeine affects HFD-induced hepatic steatosis by multifactorial intervention

Area of Science:

• Hepatology
• Nutritional Science
• Pharmacology

Background:

• Nonalcoholic fatty liver disease (NAFLD) is a growing health concern with limited therapeutic options.
• Developing cost-effective interventions for NAFLD is crucial to prevent progression to hepatic fibrosis.
• Caffeine, a widely consumed beverage, possesses known antioxidant and anti-inflammatory properties.

Purpose of the Study:

• To investigate the potential of caffeine in ameliorating liver injury induced by high-fat diet (HFD) in a rat model.
• To assess caffeine's effects on biochemical markers, oxidative stress, and gene expression related to lipid metabolism in HFD-fed rats.

Main Methods:

• Rats were divided into four groups: control, HFD, HFD + caffeine (20 mg/kg), and HFD + caffeine (30 mg/kg).
• Treatment duration was 16 weeks, with caffeine administered during the last 8 weeks.
• Liver injury was assessed via serum biochemistry, histopathology, oxidative stress markers, and gene expression analysis of lipogenic enzymes.

Main Results:

• Caffeine administration significantly reduced elevated serum ALT, AST, and bilirubin levels, while increasing albumin levels.
• Caffeine decreased hepatic mRNA expression of fatty acid synthase and acetyl CoA carboxylase.
• Caffeine treatment reduced lipid peroxidation and oxidative stress, and modulated key proteins involved in fatty acid metabolism.

Conclusions:

• Caffeine demonstrates a protective effect against HFD-induced liver injury in rats.
• Caffeine ameliorates hepatic injury by suppressing inflammation, reducing oxidative stress, and regulating lipid metabolism.
• Caffeine shows promise as a potential therapeutic or preventative agent for NAFLD.